COMBINATIONAL THERAPY ENHANCES ANTITUMOR ACTIVITY IN TUMORS RESISTANT TO IRINOTECAN TREATMENT IN A PRECLINICAL CRC MODEL

被引：0
|
作者：
Greene, J. L. [1 ]
Bagby, S. [1 ]
Messersmith, W. [1 ]
Aracaroli, J. [1 ]
机构：
[1] Univ Colorado, Aurora, CO USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2015年 / 63卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
421
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [21] Minocycline Attenuates Ototoxicity and Enhances Antitumor Activity of Cisplatin Treatment In Vitro
    Du, Bo
    Zhang, Yan
    Tang, Yong
    Wang, Ping
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2011, 144 (05) : 719 - 725
  • [22] Hypoxia-activated prodrug TH-302 enhances antitumor activity of antiangiogenics in preclinical models
    Sun, Jessica D.
    Ahluwalia, Dharmendra
    Liu, Qian
    Wang, Yan
    Meng, Fanying
    Bhupathi, Deepthi
    Curd, John G.
    Matteucci, Mark D.
    Hart, Charles P.
    CANCER RESEARCH, 2011, 71
  • [23] Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
    Daudigeos-Dubus, Estelle
    Le Dret, Ludivine
    Lanvers-Kaminsky, Claudia
    Bawa, Olivia
    Opolon, Paule
    Vievard, Albane
    Villa, Irene
    Pages, Melanie
    Bosq, Jacques
    Vassal, Gilles
    Zopf, Dieter
    Geoerger, Birgit
    PLOS ONE, 2015, 10 (11):
  • [24] Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis
    Kumar, P
    Benedict, R
    Urzua, F
    Fischbach, C
    Mooney, D
    Polverini, P
    LABORATORY INVESTIGATION, 2005, 85 (06) : 756 - 767
  • [25] Regorafenib antitumor activity alone and in combination with radio or chemotherapy in preclinical models of pediatric solid tumors.
    Daudigeos-Dubus, Estelle
    Le Dret, Ludivine
    Lanvers-Kaminsky, Claudia
    Bawa, Olivia
    Opolon, Paule
    Villa, Irene
    Bosq, Jacques
    Vassal, Gilles
    Zopf, Dieter
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors
    Wragg, Joseph W.
    Heath, Victoria L.
    Bicknell, Roy
    CANCER RESEARCH, 2017, 77 (04) : 1008 - 1020
  • [27] Preclinical antitumor activity of BMS-986158, an oral BET inhibitor, for the treatment of cancer
    Wee, Susan
    Jackson, Donald
    Desilva, Heshani
    Dajee, Maya
    Carman, Julie
    Ross-MacDonald, Petra
    Gan, Jinping
    Westhouse, Richard A.
    Huang, Christine
    Yang, Zheng
    Poss, Michael
    Hunt, John T.
    Vite, Gregory D.
    Gavai, Ashvinikumar V.
    CANCER RESEARCH, 2018, 78 (13)
  • [28] VARIATIONS IN SERUM ALKALINE DNASE ACTIVITY IN RATS DURING GROWTH AND TREATMENT OF TUMORS SENSITIVE OR RESISTANT TO THERAPY
    ECONOMIDOUKARAOGLOU, A
    BRASSEUR, F
    LANS, M
    TAPER, HS
    ROBERFROID, MB
    INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (05) : 956 - 959
  • [29] Liposomal Phenylephrine Nanoparticles Enhance the Antitumor Activity of Intratumoral Chemotherapy in a Preclinical Model of Melanoma
    Gabriel, Emmanuel M.
    Bahr, Deborah
    Rachamala, Hari Krishnareddy
    Madamsetty, Vijay S.
    Shreeder, Barath
    Bagaria, Sanjay
    Escobedo, Amber L.
    Reid, Joel M.
    Mukhopadhyay, Debabrata
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 2024, 10 (05) : 3412 - 3424
  • [30] Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment
    Loupalkis, F.
    Stasi, I
    Pollina, L.
    Masi, G.
    Baldi, G.
    Fomaro, L.
    Schiavon, G.
    Scartozzi, M.
    Petrini, I
    Santini, D.
    Funel, N.
    Campani, D.
    Tonini, G.
    Cascinu, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 14 - 14
12345